ArticleActa Cardiologica Sinica2026
Comparative Efficacy of Ticagrelor and Clopidogrel in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Cardiac Magnetic Resonance Imaging-Based Pilot Study.
Article in Acta Cardiologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ticagrelor provides faster and more consistent platelet inhibition than clopidogrel; however, its effect on myocardial injury during primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) remains uncertain. Objectives: The aim of this pilot study was to assess the feasibility and preliminary effects of ticagrelor versus clopidogrel loading on myocardial injury in STEMI patients undergoing PCI, using cardiac magnetic resonance (CMR) imaging. Methods: Thirty STEMI patients were randomized to receive aspirin with either clopidogrel (300 mg) or ticagrelor (180 mg) before PCI, followed by standard maintenance therapy. Myocardial injury was evaluated 4-10 days post-PCI using CMR parameters (infarct size, myocardial salvage index [MSI], microvascular obstruction [MVO], and infarct transmurality). Enzymatic infarct size and 5-year clinical outcomes were also analyzed. Results: No significant differences in infarct size, MSI, MVO, or other CMR parameters were detected between the two groups. Left ventricular volume and function were comparable, with no major adverse cardiovascular events, stent thrombosis, or major bleeding over the 5-year follow-up period. Conclusions: Ticagrelor and clopidogrel showed similar effects on CMR-based myocardial injury and long-term outcomes in STEMI patients undergoing PCI. These pilot findings are hypothesis-generating and support the feasibility and inform sample-size planning for future multicenter trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.